SLC5A2, solute carrier family 5 member 2, 6524

N. diseases: 214; N. variants: 20
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. 31813092 2020
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE The collective data indicate that SGLT2 inhibitors are pleiotropic agents that offer important cardiovascular, metabolic and renal benefits beyond glucose lowering with low incidences of hypoglycemia. 31839265 2020
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. 30901912 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE SGLT-2 inhibitors and SGLT-1/2 inhibitors were associated with similar rates of hypoglycaemia but a higher incidence of genitourinary infections, compared with placebo. 31081593 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE In conclusion, while the combination of metformin and SGLT2 inhibitors would be a better option in improving glycemic control with a low risk of hypoglycemia, an increase in the risk of metabolic acidosis during combination therapy may be borne in mind. 30639796 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE The unique mode of action eliminates the risk of hypoglycemia and makes SGLT2 inhibitors an attractive option for the treatment of type 2 diabetes. 30469144 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE The meta-analysis showed that, compared with the control group, the use of SGLT2 inhibitors improved both glycated hemoglobin (HbA1c) in patients (WMD - 0.73%; 95% confidence interval [CI] - 0.84, - 0.61) and the percentage of patients with HbA1c  < 7% (RR 2.33; 95% CI 1.74, 3.12); lowered both fasting plasma glucose (WMD - 28.47 mg/dl; 95% CI - 32.86, - 24.08) and postprandial glucose (WMD - 52.32 mg/dl; 95% CI - 67.67, - 39.96); reduced body weight (WMD - 1.73 kg; 95% CI - 2.28, - 1.17); and did not increase the risk of hypoglycemia (RR 1.27; 95% CI 0.89, 1.82) and urinary tract infections (RR 0.93; 95% CI 0.68, 1.27). 31376072 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE SGLT2 inhibitors did not induce hypoglycemia, severe hypoglycemia, cardiovascular events, bone fracture and all-cause mortality, but increased the risk of adverse events (AE), adverse events related to the drug treatment, infections, diabetic ketoacidosis (DKA) and renal disease correlated with dosage. 30565398 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE We report a novel complication of hypoglycemia that occurred during the course of treatment of SGLT2 inhibitor-induced DKA in a patient with type 2 diabetes mellitus (T2DM) on the dapagliflozin-metformin combination. 31489272 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. 31183975 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE Compared with SUs, SGLT2 inhibitors led to no significant reduction in changes in HbA1c (mean difference [MD] - 0.06; 95% confidence interval [CI] [- 0.12, 0.08]), but less hypoglycemia as add-on to metformin (odds ratio [OR] 0.12; 95% CI [0.07, 0.21]). 31041606 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Compared with SU initiation and after propensity score decile adjustment, new users of SGLT-2 inhibitors had a reduced risk for HF hospitalization (HR = 0.35, 95% CI = 0.13-0.89), hypoglycemia, albuminuria, microvascular disease, and metabolic failure. 31778623 2019
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE SGLT2 inhibitors may have little or no effect on the risk of cardiovascular death, hypoglycaemia, acute kidney injury (AKI), and urinary tract infection (low certainty evidence). 30246878 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE Furthermore, no disparity was found in the risk of all-cause mortality or hypoglycemia in SGLT2 inhibitors treatment between Asian and non-Asian patients. 29029369 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Regarding other adverse events, SGLT2 inhibitors do not increase the risk of hypoglycemia even when co-administered with insulin, but a decrease in the dose of sulphonylureas may be needed. 29039237 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria, or volume depletion. 29507611 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic agents which exerts their effects insulin-independent mechanism, therefore, they do not cause hypoglycemia in the diabetic patients. 29673309 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE ADRs of special interest that had been reported in clinical trials of SGLT2 inhibitors, such as hypoglycemia, volume depletion-related events, genital/urinary tract infection, polyuria/pollakiuria, and ketone body increased were also observed in this PMS. 29025285 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials. 29334278 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE However, there are no comparative studies on the effects of SGLT2 inhibitors and DPP4 inhibitors on HbA1c, body weight and hypoglycemia as risk factors of cardiovascular diseases. 29895330 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 Biomarker disease BEFREE There was no significant increase in the rate of hypoglycaemia or severe hypoglycaemia; however, SGLT2 inhibitor therapy increased diabetic ketoacidosis (odds ratio [OR] 3.38) and genital tract infection (OR 3.44). 29451721 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Results for third-line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT-2 inhibitors and GLP-1RAs, and a slightly greater reduction in body weight with SGLT-2 inhibitors vs GLP-1RAs. 29205774 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE In the patients with T2D and moderate renal function impairment (30 ml/min/1.73 m<sup>2</sup> ≤ estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m<sup>2</sup>) compared with the placebo, SGLT2 inhibitors improved HbA1c significantly (WMD, -0.23%; 95% CI: -0.38 to -0.08), presented a lower incidence of hypoglycemia (30.1% vs. 34.6%; RR, 0.85; 95% CI: 0.76 to 0.96), led to the reduction of eGFR (WMD, -1.74 ml/min/1.73 m<sup>2</sup>; 95% CI: -3.45 to -0.03), resulted in an obvious reduction in body weight (WMD, -1.45 kg; 95% CI: -2.01 to -0.89), and presented a similar risk of urinary tract infection and genital infection. 29649541 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE Continued use of SGLT2 Inhibitors during Ramadan did not increase ketonemia, nor increase risk of eGFR deterioration and hypoglycaemia. 29802956 2018
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia
0.100 GeneticVariation disease BEFREE In this retrospective series, acute ingestions of SGLT2 inhibitors were well-tolerated with no hypoglycemia and only minor effects. 28812381 2018